Wang Ru, Hu Jing, Li Yuanyuan, Yin Hong
Department of Pharmacy, Medical Supplies Center, PLA General Hospital, Beijing 100853, China.
Chin Herb Med. 2024 Mar 27;16(4):622-637. doi: 10.1016/j.chmed.2023.12.005. eCollection 2024 Oct.
To evaluate the efficacy of Compound Danshen Dripping Pills (CDDP) combined with isosorbide mononitrate (ISMN) versus ISMN alone for treating angina pectoris in patients.
The PubMed, Web of Science, Cochrane Library, Embase China National Knowledge Infrastructure, China Biomedical Literature Service System, Chinese Medical Journal Database, and Wan Fang MED databases were searched from inception to November 2022. Randomized controlled trials (RCTs) and cohort studies were included. The primary outcomes were angina symptom and electrocardiography (ECG) efficacy, angina symptom efficacy, and ECG efficacy. The protocol was registered with PROSPERO No. CRD42022314774.
Our study included 7 245 patients with angina (59 RCTs, 11 cohort studies). When ISMN was combined with CDDP, the efficacy of angina symptom and ECG [odds ratio (OR) = 4.824, 95% confidence interval (CI) = 3.636-6.401, = 0.000], the efficacy of angina symptom (OR = 4.347, 95% CI = 3.635-5.198, = 0.000), the efficacy of ECG (OR = 3.364, 95% CI = 2.767-4.089, = 0.000) were better than that of patients treated with ISMN alone. CDDP combined with ISMN was superior to ISMN alone in reducing triglyceride (TG) [mean difference (MD) = -35.176, 95% CI = -37.439 to -32.912, = 0.000], total cholesterol (TC) (MD = -24.296, 95% CI = -26.429 to -22.163, = 0.000), the duration of angina attack (MD = -1.991, 95% CI = -2.349 to -1.633, = 0.000), and the frequency of angina attack [standardized MD (SMD) = -2.840, 95% CI = -3.416 to -2.265, = 0.000]. There was no increase in adverse events between CDDP combined with ISMN and ISMN alone (OR = 0.513, 95% CI = 0.421-0.626, = 0.000).
CDDP combined with ISMN improved treatment efficacy and was well tolerated. Therefore, this combination could be used as an alternative treatment. However, clinical and patient conditions should be considered.
评估复方丹参滴丸(CDDP)联合单硝酸异山梨酯(ISMN)与单用ISMN治疗患者心绞痛的疗效。
检索了从建库至2022年11月的PubMed、Web of Science、Cochrane图书馆、中国知网、中国生物医学文献服务系统、中华医学期刊数据库和万方医学数据库。纳入随机对照试验(RCT)和队列研究。主要结局为心绞痛症状和心电图(ECG)疗效、心绞痛症状疗效和ECG疗效。该方案已在国际前瞻性注册平台(PROSPERO)注册,注册号为CRD42022314774。
我们的研究纳入了7245例心绞痛患者(59项RCT,11项队列研究)。当ISMN与CDDP联合使用时,心绞痛症状和ECG疗效[比值比(OR)=4.824,95%置信区间(CI)=3.636-6.401,P=0.000]、心绞痛症状疗效(OR=4.347,95%CI=3.635-5.198,P=0.000)、ECG疗效(OR=3.364,95%CI=2.767-4.089,P=0.000)均优于单用ISMN治疗的患者。CDDP联合ISMN在降低甘油三酯(TG)[平均差(MD)=-35.176,95%CI=-37.439至-32.912,P=0.000]、总胆固醇(TC)(MD=-24.296,95%CI=-26.429至-22.163,P=0.000)、心绞痛发作持续时间(MD=-1.991,95%CI=-2.349至-1.633,P=0.000)和心绞痛发作频率[标准化MD(SMD)=-2.840,95%CI=-3.416至-2.265,P=0.000]方面优于单用ISMN。CDDP联合ISMN与单用ISMN相比,不良事件没有增加(OR=0.513,95%CI=0.421-0.626,P=0.000)。
CDDP联合ISMN提高了治疗效果,且耐受性良好。因此,这种联合用药可作为一种替代治疗方法。然而,应考虑临床和患者情况。